Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.41 |
| ▸ | GALR1 | P47211 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883455 | 0.97 | TRPV1 (0.50) | TRPV1HSD11B1TRPA1HRH4GALR2 | |
| SCHEMBL3876748 | 0.91 | TRPV1 (0.52) | TRPV1HSD11B1RBP4 | |
| SCHEMBL3878477 | 0.90 | TRPV1 (0.50) | TRPV1HSD11B1TRPA1HRH4GALR2 | |
| SCHEMBL3884278 | 0.90 | TRPV1 (0.50) | TRPV1HSD11B1TRPA1GALR2GALR1 | |
| SCHEMBL3888400 | 0.90 | TRPV1 (0.54) | TRPV1HSD11B1TRPA1 | |
| SCHEMBL3877173 | 0.90 | TRPV1 (0.48) | TRPV1HSD11B1GALR2GALR1 | |
| SCHEMBL3878982 | 0.90 | TRPV1 (0.49) | TRPV1HSD11B1HRH4 | |
| SCHEMBL3891470 | 0.89 | HSD11B1 (0.49) | TRPV1HSD11B1TRPA1 | |
| SCHEMBL14613928 | 0.89 | HSD11B1 (0.49) | TRPV1HSD11B1TRPA1 | |
| SCHEMBL3880583 | 0.89 | TRPV1 (0.50) | TRPV1HSD11B1GALR2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | claimed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | TRPV1 244/4885HSD11B1 3915/4885TRPA1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.